Gå direkt till innehåll
Scandinavian Biopharma announces the last follow up visit in the phase IIB clinical trial with ETVAX® in Finnish travellers to Benin

Pressmeddelande -

Scandinavian Biopharma announces the last follow up visit in the phase IIB clinical trial with ETVAX® in Finnish travellers to Benin

In record time Scandinavian Biopharma completed a phase IIB randomized, double-blind, placebo-controlled trial in Finnish travellers going to Benin in West Africa. All participantshave now been enrolled and the last travellers left Benin in March 2019. The last follow up visit was conducted just before Easter. In total 743 healthy travellers, between the ages of 18 to 65 years, have spent a fortnight in Benin. Half of the group were given the ETEC vaccine candidate, ETVAX®, and the other half placebo. The aim of the study was to evaluate safety, new diagnostic methodology and estimate the protective efficacy of the vaccine against ETEC caused travellers’ diarrhoea (TD) in a naive population.

The trial is a successful collaboration between the University of Helsinki, University of Gothenburg and Scandinavian Biopharma. Other partners include the Aava travel clinic, United Medix Laboratories Ltd, Medfiles Ltd and University of Virginia. The study was funded by Scandinavian Biopharma, European Research and Innovation Program Horizon 2020 (SME), the international health organisation PATH and Bill & Melinda Gates Foundation.

The Finnish-African cultural centre Villa Karo in Benin and Finland has been responsible for taking care of all participants during the trip. To proceed with the study, Scandinavian Biopharma built a fully equipped laboratory at the local site in Grand Popo, Benin. The study enrolment has been very successful with the inclusion of 743 participants. Primary results show that the incidence of TD is very high; ETEC is the most common pathogen; the vaccine has been safe and well tolerated and the vaccine coverage is as high as almost 90%. All samples from the clinical trial are now being analysed and later this year the study will be unblinded and presented.

The most common illness that affects travellers visiting sub/tropical regions is TD. It is estimated that up to 30-40% of travellers can experience TD during a two-week stay. ETEC is the most common cause of travellers’ diarrhoea affecting 35 million travellers to (sub) tropical destinations every year. Recent data also strongly suggest that ETEC infections in travellers also can increase the risk of subsequent functional bowel disorders. In fact, 10-14 % of travellers convalescing from ETEC-associated TD may go on to develop irritable bowel syndrome, thus further highlighting the importance of disease prevention and the potential benefit of having effective vaccines.

Björn Sjöstrand, CEO at Scandinavian Biopharma, says: “Our vaccine can make a big difference by saving millions of well-deserved holiday trips and prevent negative long-term gastrointestinal syndromes. Positive results will accelerate the development of our tailor-maid presentation for infants in Low- and Middle-Income Countries where ETVAX® could have the potential to save hundred thousands of lives and reduce morbidity leading to poor physical and cognitive development among infants.”

For more information, please contact:Björn Sjöstrand, CEO: +46 727-125 120, bjorn.sjostrand@scandinavianbiopharma.se

Ämnen

Kategorier


Scandinavian Biopharma

Scandinavian Biopharma is a Swedish research-based biotech company specialist in marketing and sales of vaccines, immunoglobulin’s, biodefense, antidotes and diagnostic tests.

Research and development is mainly focused on development of a new oral traveler’s diarrhea vaccine in collaboration with PATH Vaccine Solutions and University of Gothenburg.

www.scandinavianbiopharma.se

Kontakter

Björn Sjöstrand

Björn Sjöstrand

Presskontakt VD +46 (0)72 712 51 20

Relaterat innehåll

Nu tar vi nästa steg mot ett nytt ETEC vaccin

Nu tar vi nästa steg mot ett nytt ETEC vaccin

Nu startar vi rekryteringen till vår nästa studie. Tillsammans med forskare från Helsingfors universitet, Göteborgs universitet och Johns Hopkins University ska säkerheten och den kliniska effekten av vårt ETEC-vaccin testas i en placebokontrollerad fas IIb studie. Studien, som löper under minst ett år, ska göras på finska resenärer som ska resa till Benin i Afrika

Villa Karos ordförande Juha Vakkuri under invigningen

Högtidlig invigning av laboratoriet i Benin

För tre månaders sedan började vi bygga ett nytt laboratorium – i Benin i Afrika. Det är här som proverna från vår placebokontrollerade fas IIb-studie på vårt ETEC-diarrévaccin kommer att analyseras. Laboratoriet står nu klart och den stora invigningen ägde rum i början av maj.

Principal investigator Professor Anu Kantele visiting Benin

Promising preliminary findings from a Phase 2b study of the oral vaccine ETVAX® against travelers’ diarrhea in Finnish travelers to Benin, West Africa

Encouraging results from a Phase 2b study. The trial enrolled adult volunteers from Finland who travelled to Benin after receiving ETVAX® or placebo. The study results confirm the excellent safety and overall positive immunogenicity of ETVAX®, as well as a significant protective efficacy of 56% against all severe diarrhea, independent of pathogen.

The successful immunogenicity and safety results of ETVAX® are presented at Vaccines for Enteric Diseases (VED) Oct 16-18 in Lausanne, Switzerland

The successful immunogenicity and safety results of ETVAX® are presented at Vaccines for Enteric Diseases (VED) Oct 16-18 in Lausanne, Switzerland

Today we will present the excellent results from multiple completed and on-going clinical trials of ETVAX® at VED - a conference that addresses the diverse aspects of vaccines to counter human enteric diseases. In the light of global public health issues, enteric diseases are estimated to be the top cause of infectious morbidity and the second leading cause of infectious mortality worldwide.

Vi är ett forskningsbaserat biotechföretag fast beslutna att ge människor i hela världen ett längre och bättre liv.

Vi utvecklar det första vaccinet i världen mot diarré orsakad av ETEC för att skydda både barn och vuxna i endemiska länder och resenärer till högriskdestinationer.

Vi distribuerar ett brett sortiment av biologiska specialistläkemedel med fokus på vacciner och immunglobuliner.

www.scandinavianbiopharma.se

Vår information på mynewsdesk riktar sig till journalister och media.

Scandinavian biopharma

Industrivägen 1, vån 4
171 48 Solna
Sverige